238 related articles for article (PubMed ID: 24716717)
1. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
[TBL] [Abstract][Full Text] [Related]
2. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Carlson JJ; Wong WB; Veenstra DL; Reyes C
J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
5. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Graham J; Earnshaw S; Burslem K; Lim J
J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
Ramsey SD; Clarke L; Kamath TV; Lubeck D
J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
[TBL] [Abstract][Full Text] [Related]
7. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib for the treatment of relapsed non-small cell lung cancer.
McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
10. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic review of erlotinib in non-small-cell lung cancer.
Yeung K; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
14. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
[TBL] [Abstract][Full Text] [Related]
17. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
18. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
[TBL] [Abstract][Full Text] [Related]
19. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
20. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]